Astralis Ltd. Selects Allen & Caron for Corporate Communications, Investor and Media Relations FAIRFIELD, N.J., May 3 /PRNewswire-FirstCall/ -- Astralis Ltd. (BULLETIN BOARD: ASTR) a biotechnology company engaged in the research and development of novel treatments for immune system disorders and skin diseases, announced that it has selected Irvine, CA-based Allen & Caron Inc as its corporate communications, investor relations and media relations agency. Astralis currently has one product in clinical development, Psoraxine(R), now in Phase II clinical trials, for the treatment of psoriasis. A proprietary protein extract, Psoraxine represents an innovative approach to the treatment of the disease, as it appears to act through a mechanism of immuno-stimulation, as opposed to the immuno-suppression techniques used by some existing biologic therapies. The Company also has pre-clinical focus in other areas including eczema, seborrheic dermatitis, psoriatic arthritis, rheumatoid arthritis and leishmaniasis. Astralis CEO Mike Ajnsztajn commented, "We have arrived at the place in our strategic plan that calls for increased communication with professional investment audiences, both in the US and abroad, and we have selected Allen & Caron due to their experience and ability in assisting companies wishing to position themselves properly within the investment community. We believe that Allen & Caron should be able to help us with the dissemination of our corporate information to the Street, as well as to industry and financial media." Allen & Caron Chairman and CEO, Joe Allen, said, "Astralis's proprietary technology platform, and resulting therapy, Psoraxine, position the Company in front of some very large potential market opportunities. According to the National Psoriasis Foundation, psoriasis affects more than 4.5 million people in the US alone. We believe that Astralis presents an interesting and compelling story to Wall Street and we look forward to working with them to broaden their audience, by increasing overall awareness among US institutional investors and the international media." About Allen & Caron Inc Allen & Caron is a full service corporate, investor and marketing communications agency serving the needs of public companies. The Allen & Caron international client base includes emerging growth companies in a range of industry segments. The firm maintains offices in Irvine, CA, New York City and London. For more information, please visit http://www.allencaron.com/. About Astralis Ltd. Fairfield, NJ-based Astralis is a development-stage biotechnology company engaged in the research and development of novel treatments for immune system disorders and skin diseases. The Company's current activities focus on the development of a product candidate named Psoraxine(R) -- now in Phase II clinical trials -- for the treatment of psoriasis. Psoraxine is a proprietary protein extract with a mechanism of action that is believed to be based on immuno-stimulation. Astralis is also engaged in research on the possible development of the technology underling Psoraxine for the treatment of other indications, such as eczema, seborrheic dermatitis, psoriatic arthritis, rheumatoid arthritis and leishmaniasis. In January 2004, Astralis received its first patent from the United States Patent Office. For more information, please visit http://www.astralisltd.com/. This press release may contain "forward-looking statements", as defined by the Private Securities Litigation Reform Act of 1995, regarding Astralis Ltd., including with respect to the objectives, intentions, and expectations relating to clinical studies. Clinical results may differ materially from those described in the press release as a result of a number of factors. There can be no assurance that Psoraxine(R) will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of this product will be achieved. Other factors that could cause actual results to differ materially from anticipated results include, but are not limited to, those risks and uncertainties detailed in the Company's annual report on Form 10-KSB and other reports filed from time to time with the Securities and Exchange Commission. Astralis Ltd. undertakes no obligation to revise or update any forward-looking statement herein to reflect events or circumstances after the date of this release. For further information, please contact: Investors, Jay F. McKeage, , or Media, Brian Kennedy, , both of Allen & Caron Inc, +1-212-691-8087, for Astralis Ltd.; or Mike Ajnsztajn, Chief Executive Officer, or Gina Tedesco, Chief Financial Officer, both of Astralis Ltd., +1-973-227-7168, . DATASOURCE: Allen & Caron Inc CONTACT: investors, Jay F. McKeage, , or media, Brian Kennedy, , both of Allen & Caron Inc, +1-212-691-8087, for Astralis Ltd.; or Mike Ajnsztajn, Chief Executive Officer, or Gina Tedesco, Chief Financial Officer, both of Astralis Ltd., +1-973-227-7168, Web site: http://www.astralisltd.com/ Web site: http://www.allencaron.com/ Company News On-Call: http://www.prnewswire.com/comp/133897.html

Copyright